Form 4: Avidity Biosciences CHRO Sells Shares Under 10b5-1 Plan

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, exercised stock options and sold 15,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, Inc., reported transactions on September 15, 2025.
• McCarthy exercised options to acquire 15,000 shares of common stock at an exercise price of $22.34 per share.
• Concurrently, McCarthy sold 15,000 shares of common stock at a weighted-average price of $41.4095 per share, with individual sales ranging from $40.02 to $44.47.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan previously adopted on April 11, 2025.
• Following these transactions, McCarthy directly owns 97,130 shares of common stock and 85,000 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which mitigates the negative signal typically associated with insider selling. It represents a routine financial planning event for the executive.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the decision to sell was made in advance and not based on recent non-public information.
• The sale price of $41.4095 per share is significantly higher than the exercise price of $22.34 per share, indicating a profitable transaction for the insider.

Negatives

• An insider sale of 15,000 shares by a Chief Human Resources Officer could be perceived as a negative signal by some investors, even if pre-planned.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 11, 2025.

Industry Context

Insider transactions, particularly sales, are closely watched by investors as they can sometimes signal management's perception of the company's future prospects. However, sales executed under a Rule 10b5-1 plan are generally viewed with less concern, as they are pre-scheduled and not indicative of a reaction to recent non-public information. Such plans are common among executives for personal financial planning and diversification.

Comparison to Industry Standards

• This filing reports a routine insider transaction (exercise and sell-to-cover or diversification sale) under a Rule 10b5-1 plan, which is a standard practice for corporate executives in publicly traded companies across various industries, including biotechnology. There are no specific comparable companies or projects mentioned in this Form 4 to assess against global benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns. The profitable nature of the transaction for the insider could be seen positively as it reflects stock appreciation.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction (exercise of options and sale of shares) by a Chief Human Resources Officer. While it's an insider sale, the execution under a Rule 10b5-1 plan significantly reduces its signaling value regarding the company's future prospects. It appears to be a personal financial planning event rather than a reaction to new material information. Therefore, it does not provide a strong basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as it doesn't fundamentally alter the investment thesis for Avidity Biosciences.

Keywords

Avidity Biosciences, RNA, Teresa McCarthy, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Chief Human Resources Officer